Urinary incontinence (UI) is a health problem with considerable social and economic impact. According to the National Association for Continence, UI affects over 25 million people in the US, 75-80% of which are women.
Dropsordry is a natural ingredient containing genistein from SOLGEN soybean isoflavones and enterodiol from a standardised pumpkin seed extract. Enterodiol from Dropsordry seems to interact with receptors on the levator ani muscle, triggering an anabolic effect on pelvic muscles. It was previously shown that genistein from the Dropsordry compound regressed degenerative changes associated at overactive bladder (OAB) symptoms.
It has been reported that oestrogen deficit seems to be related to the increase in muscarinic receptors, which mediate reflexive bladder contractions. Nervous dysregulation is the cause of OAB and urinary incontinence is a consequence. Dropsordry supplementation was tested in 82 perimenopausal European women diagnosed with urinary incontinence - aged 42-62 years with a mean age of 52 - over a two-month period, with promising results in relieving some urinary incontinence symptoms.
After eight weeks of supplementation, the use of daily underwear liners was reduced by 69.35% compared with the baseline (see Figure 1). There was a trend in the reduction of total urge episodes with a decrease of 46%, and nocturia was reduced by 66.25%.
In accordance with International Conference Society guidelines, a questionnaire was performed before and after supplementation, which showed that 96.2% of subjects reported satisfaction with the treatment and a 92.3% of improvement in their quality of life. No side effects were described.